IMGN - ImmunoGen: Possible Accelerated FDA Approval For Ovarian Cancer Treatment
- PDUFA date with Priority Review for mirvetuximab for treatment of ovarian cancer patients with high folate receptor alpha set for November 28, 2022.
- Confirmatory MIRASOL study trial readout of mirvetuximab for treatment of ovarian cancer patients with high folate receptor alpha expected early 2023.
- Results from phase 2 CADENZA study using pivekimab sunirine for treatment of frontline and relapsed/refractory blastic plasmacytoid dendritic cell neoplasm patients expected before end of 2022.
- Results from phase 1b/2 triple combination study using pivekimab sunirine + Azacitidine + Venetoclax for the treatment of patients with acute myloid leukemia expected before end of 2022.
For further details see:
ImmunoGen: Possible Accelerated FDA Approval For Ovarian Cancer Treatment